id-lv305
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2014 (NCT02122861)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- id-lv305
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03450122 | Phase 1 | Sep 13, 2018 | Immune Design, University of Texas at Houston |
| NCT02122861 | Phase 1 | May 1, 2014 | Immune Design, Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immune Design | For profit | 2 | 1 | 1 | 2014 |
| Merck | For profit | 1 | 0 | 1 | 2014 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1